Crinetics Pharmaceuticals, Inc. (CRNX)

Price$32.92

Value ScoreD

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-35.67%

Price vs S&P 500 (4W)-12.16%

VGM Score54.24

Market Capitalization$3.47B

All Metrics

Book Value / Share (Quarterly)$12.16

P/TBV (Annual)6.76x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.53%

Cash Flow / Share (Quarterly)$-3.98

Price vs S&P 500 (YTD)-37.44%

Net Profit Margin (TTM)-2747.18%

EPS (TTM)$-5.13

10-Day Avg Trading Volume0.98M

EPS Excl Extra (TTM)$-5.13

Revenue Growth (5Y)156.00%

EPS (Annual)$-4.95

ROI (Annual)-46.90%

Gross Margin (Annual)86.02%

Net Profit Margin (5Y Avg)-10707.53%

Cash / Share (Quarterly)$12.26

Revenue Growth QoQ (YoY)2873.41%

ROA (Last FY)-41.32%

Revenue Growth TTM (YoY)2277.50%

EBITD / Share (TTM)$-5.59

ROE (5Y Avg)-38.69%

Operating Margin (TTM)-3020.32%

Cash Flow / Share (Annual)$-4.01

P/B Ratio2.71x

P/B Ratio (Quarterly)2.97x

Net Income / Employee (Annual)$-783,400

EV / Revenue (TTM)185.77x

ROA (TTM)-39.61%

EPS Incl Extra (Annual)$-4.95

Current Ratio (Annual)12.32x

Quick Ratio (Quarterly)18.37x

3-Month Avg Trading Volume1.14M

52-Week Price Return1.86%

Revenue / Employee (TTM)$30,400

Tangible BV / Share (Quarterly)$8.21

P/S Ratio (Annual)451.03x

Asset Turnover (Annual)0.01x

52-Week High$57.99

Operating Margin (5Y Avg)-11677.88%

EPS Excl Extra (Annual)$-4.95

CapEx CAGR (5Y)97.86%

Tangible BV CAGR (5Y)84.80%

26-Week Price Return-27.74%

Quick Ratio (Annual)12.09x

13-Week Price Return-15.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)18.60x

Enterprise Value$3.36B

Revenue / Share Growth (5Y)104.27%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)15.19%

Revenue / Employee (Annual)$13,000

Pretax Margin (Annual)-6043.88%

Cash / Share (Annual)$10.75

3-Month Return Std Dev52.11%

Net Income / Employee (TTM)$-835,700

ROE (Last FY)-46.90%

EPS Basic Excl Extra (Annual)$-4.95

Receivables Turnover (TTM)0.68x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.13

Receivables Turnover (Annual)2.52x

ROI (TTM)-43.96%

P/S Ratio (TTM)192.10x

Pretax Margin (5Y Avg)-10667.85%

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$5.87

Price vs S&P 500 (52W)-22.51%

Year-to-Date Return-29.28%

5-Day Price Return-4.63%

EPS Normalized (Annual)$-4.95

ROA (5Y Avg)-34.62%

Net Profit Margin (Annual)-6046.22%

Month-to-Date Return-7.40%

Cash Flow / Share (TTM)$-3.61

EBITD / Share (Annual)$-5.45

Operating Margin (Annual)-6714.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-38.69%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.13

P/TBV (Quarterly)3.90x

P/B Ratio (Annual)4.45x

Pretax Margin (TTM)-2746.18%

Book Value / Share (Annual)$10.38

Price vs S&P 500 (13W)-23.63%

Beta0.26x

Revenue / Share (TTM)$0.17

ROE (TTM)-43.96%

52-Week Low$25.83

vGradeD

gGradeA

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-1.23est. -1.26

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.23

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRNXCrinetics Pharmaceuticals, Inc.	D	A	C	$32.92
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company developing treatments for rare endocrine diseases and endocrine-related tumors. Its lead product, Palsonify (paltusotine), is an FDA-approved once-daily oral treatment for acromegaly in patients with inadequate response to surgery or for whom surgery is not an option. The pipeline includes late-stage candidate atumelnant for adrenal disorders and CRN09682 targeting specific neuroendocrine tumors.